

Supplementary Table 1. Literature review of published case reports, small series, and clinical trials were compiled to inform and substantiate the experience and opinion of the Working Group authors (Sources for Table 1).

*Beckham TH, Yang JC, Chau KW, Noy A, Yahalom J. Excellent Outcomes with Surgery or Radiotherapy in the Management of Castleman Disease Including a Case of Oligocentric Disease [published online ahead of print, 2020 May 11]. *Clin Lymphoma Myeloma Leuk*. 2020;S2152-2650(20)30218-4. doi:10.1016/j.clml.2020.05.002

Boutboul, David, et al. "Treatment and Outcome of Unicentric Castleman Disease: a Retrospective Analysis of 71 Cases." *British Journal of Haematology*, 2019, doi:10.1111/bjh.15921.

Dispenzieri, Angela, et al. "The Clinical Spectrum of Castleman's Disease." *American Journal of Hematology*, vol. 87, no. 11, 2012, pp. 997–1002., doi:10.1002/ajh.23291.

He, Xiaotong, et al. "Comprehensive Analysis of 225 Castleman's Diseases in the Oral Maxillofacial and Neck Region: a Rare Disease Revisited." *Clinical Oral Investigations*, vol. 22, no. 3, 2017, pp. 1285–1295., doi:10.1007/s00784-017-2232-x.

Jiang, Jin-Peng, et al. "A Retrospective Study of 34 Patients with Unicentric and Multicentric Castleman's Disease: Experience from a Single Institution." *Oncology Letters*, 2017, doi:10.3892/ol.2017.7625.

Lan, Xuan, et al. "Analysis of Clinical Characteristics and Prognosis Factors of 71 Cases with HIV-Negative Castleman's Disease: Hypoproteinemia Is an Unfavorable Prognostic Factor Which Should Be Treated Appropriately." *Journal of Cancer Research and Clinical Oncology*, vol. 144, no. 7, 2018, pp. 1265–1277., doi:10.1007/s00432-018-2647-z.

Luo, Jin Mei, et al. "Clinical Spectrum of Intrathoracic Castleman Disease: a Retrospective Analysis of 48 Cases in a Single Chinese Hospital." *BMC Pulmonary Medicine*, vol. 15, no. 1, 2015, doi:10.1186/s12890-015-0019-x.

Prakash, Gaurav, et al. "Presentation and Outcome of Castleman's Disease in Immunocompetent Hosts." *Indian Journal of Hematology and Blood Transfusion*, vol. 32, no. 4, 2015, pp. 468–474., doi:10.1007/s12288-015-0602-6.

Sopfe, Jenna, et al. "Castleman Disease in Pediatrics: Insights on Presentation, Treatment, and Outcomes from a Two-Site Retrospective Cohort Study." *Pediatric Blood & Cancer*, vol. 66, no. 5, 2019, doi:10.1002/psc.27613.

Uysal, Bora, et al. "Castleman's Disease and Radiotherapy: A Single Center Experience." *Journal of Cancer Research and Therapeutics*, vol. 11, no. 1, 2015, p. 170., doi:10.4103/0973-1482.140766.

Wang L, Nong L, Li F, et al. Predominant Stroma-Rich Feature in Hyaline Vascular Variant of Castleman Disease Is Associated With Paraneoplastic Pemphigus [published online ahead of print, 2020 May 27]. *Am J Clin Pathol*. 2020;aqaa053. doi:10.1093/ajcp/aqaa053

Wang, Shuai, et al. "Clinicopathological Characteristics of Unicentric Retroperitoneal Castleman's Disease: a Study of 14 Cases." *World Journal of Surgical Oncology*, vol. 14, no. 1, 2015, doi:10.1186/s12957-015-0756-6.

Zhang, Jun, et al. "Clinical and Experimental Study of Castleman Disease in Children." *Pediatric Blood & Cancer*, vol. 62, no. 1, 2014, pp. 109–114., doi:10.1002/pbc.25220.

Zhang, Xuanye, et al. "Clinical Characteristics and Outcomes of Castleman Disease: A Multicenter Study of 185 Chinese Patients." *Cancer Science*, vol. 109, no. 1, 2017, pp. 199–206., doi:10.1111/cas.13439.

Zhou, N, et al. "The Characterization and Management of Castleman's Disease." *The Journal of International Medical Research*, no. 40, 2012, pp. 1580–1588.